AI researchers and developers across the U.S. received a powerful if overshadowed shot in the arm on New Year’s Day.

The FDA has cleared UK-based Ultromics to sell an AI-powered tool for diagnosing coronary artery disease (CAD) on echocardiograms.

Gastroenterologists need not fear being replaced by machines—and patients don’t have to worry about robot colonoscopists.

Detecting diabetic retinopathy on eyeball imaging has been touted as one of medical AI’s most promising applications, as “the machine” has repeatedly equaled or bested humans at the task.

Of 52 AI models analyzed by MIT’s Center for Information Systems Research over the past two years, 31 have been deployed. The rest were in pilot phases or under development.

Academic experts in disaster response have developed an AI-based simulation model that accurately predicts ebbs and flows in traffic at drive-through vaccination stations.

Researchers have demonstrated two deep learning tools aimed at uncovering the psychology of aging.

Now comes a boomlet in vendors looking to piggyback on Viz.ai’s success, according to Niall Brennan, MPP, a member of Viz.ai’s advisory board who is also the head of the Healthcare Cost Institute.

CDC researchers are estimating that asymptomatic COVID-19 carriers account for at least half of all community transmissions. This includes carriers who never develop symptoms as well as those who later do.

Among the many Americans refusing to get vaccinated against COVID-19 when their turn comes up is a prominent surgeon who’s also a professional medical communicator and a Johns Hopkins public-health professor.

It’s not inconvenience or expectations of long waits that are prompting the deliberated refusals.